DBV Technologies has developed an innovative approach to influencing the immune response by targeting antigen presenting cells present in the skin. Immunoactive compounds are delivered to the immune system using DBV Technologies’ unique worldwide patented delivery system: VIASKIN®.
The key advantage of the VIASKIN® delivery system is its ability to deliver proteins epicutaneously, without any alteration in their antigenicity/allergenicity.
The key component of VIASKIN®’s ability in delivering proteins to the epidermis is its condensation chamber. This condensation chamber allows the release of soluble proteins from its backing and enables hyper hydration of the skin, which facilitates the delivery of the proteins to the epidermis. The application of VIASKIN® leads to a rapid, durable and homogenous increase in the hydration of all epidermis layers by more than 70%, after one hour of application.
The same degree of hydration was observed when VIASKIN® was applied to different age groups, ethnic groups, genders and at different temperatures. The size of the compound-holding condensation chamber is flexible and easily variable. The amount of active material can be precisely adjusted to a range from a few micrograms to several hundred, while the permeability of the polymeric film-backing can also be altered to meet specific product requirements and applications.
The key advantages of the VIASKIN® technology include:
CNIL number: 1544201 v 0
DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83
SIRET: 441772522 00013
Executive editor: Pierre-Henri Benhamou
Hosting service: OVH www.ovh.com
Design : l’enchanteur www.lenchanteur.com